参芪扶正注射液辅助NP方案治疗老年晚期非小细胞肺癌的观察及护理  

The short-term observation of Shenqifuzheng injection combined with NP chemotherapy in treating elder patients with advanced non-small cell lung cancer

作　　者：汪秀云[1] 黄宗琼[1] 李虹[1] 蔡雪彬[1] 

机构地区：[1]四川大学华西医院肿瘤中心二病房,成都610041

出　　处：《中国肺癌杂志》2007年第3期234-236,共3页Chinese Journal of Lung Cancer

摘　　要：背景与目的非小细胞肺癌(NSCLC)约占肺癌的80%,其中70%～80%为晚期肺癌,化疗为其主要治疗手段。本研究拟观察参芪扶正注射液辅助NP方案治疗老年晚期NSCLC的疗效及护理。方法将患者随机分组,其中治疗组35例,对照组34例。两组均接受NP方案治疗,长春瑞滨(NVB)25mg/m2静脉滴注,第1、8天,顺铂(PDD)30mg静脉滴注,第1～4天。治疗组化疗期间常规静脉滴注参芪扶正注射液250mL,每日1次,连用10天。结果两组近期疗效差异无显著性(P>0.05)。治疗组血液毒性反应和恶心、呕吐发生率明显低于对照组,差异有显著性(P<0.05)。所有不良反应均能耐受。结论参芪扶正注射液辅助NP方案治疗老年晚期NSCLC安全有效,参芪扶正注射液对老年晚期NSCLC化疗有一定减毒作用。Background and objective About 80% lung cancer is non-small cell lung cancer (NSCLC) and 70%--80% are in advanced stage. Chemotherapy is main treatment method. The aim of this study is to compare the therapeutic effects and toxicity of NP regimen combined with Shenqifuzheng injection on elder patients with advanced NSCLC. Methods Totally 69 patients enrolled into this study and were randomized into two groups: treatment group (35 patients) and control group (34 patients). Each patient received NVB 25mg/m2 intravenously at days 1 and 8 and DDP 30mg intravenously from 1st day to 4th day. Shenqifuzheng injection was used in the treatment group by 250mL per day for 10 days. Results There was no significant difference of the response rate between two groups (45.7% vs 41.2%, P>0.05). The hematological toxicity, nausea and vomiting in the treatment group were lower than those in the control group with significant difference (P<0.05). The adverse effects were well tolerable. Conclusion NP regimen combined with Shenqifuzheng injection on elder patients with advanced NSCLC is effective and safe. Shenqifuzheng injection has definite toxicity relieving effect on treating elder patients with advanced NSCLC.

关 键 词：参芪扶正注射液 非小细胞肺癌 化疗 老年人 护理 

分 类 号：R473.73[医药卫生—护理学]